1Wong T Y, Chan P K, Leung C B, et al. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. Am J Kidney Dis, 1999,36:1132-1136.
2Suzuki S, Osaka Y, Nakai I, et al. Pure red cell aplasia induced by FKS06. Transplantation, 1996, 61: 831-832.
4Katari SR, Mangnone M, Shapiro R, et al. Tacrolimus nephrotoxicity after renal transplantation [ J ]. Transplant Proc, 1997, 29(1- 2) :311.
5Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. mulficenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group [ J ]. Transplantation, 1998, 66(12) : 1 736.
6Undre NA, Stevenson P, Schafer A. Pharmacokinetics of tacrolimus: clinically relevant aspects [J]. Transplant Proc, 1999, 31(7A) :21s.
7Wingard JR, Nash RA, Prepiorka D, et al. Relationship of tacrolimus (FK 506) whole blood concentrations and efficacy and safety after HLA - identical sibling bone marrow transplantation[J]. Biol Blood Marrow Transplant, 1998, 4 (3) : 157.
9Pirsch JD, Miller J, Deierhoi MH, et al. A comparion of tacrolimus (FK506)and cyclosporine for immunosuppression after cadaveric renal transplantation [ J ]. Transplantation, 1997, 63(7) :977.
10Rinald M, Pellegrini C, Martinelli L. FK506 effectiveness in reducing actue rejection after heart transplantation : a prospective randomized study [ J ]. J Heart Lung Transplant, 1997, 16(10) : 1 001.
